Home > Inhibitors & Agonists > Cell Cycle/DNA Damage > ATM/ATR
Cat. No. Product name CAS No.
DC10906 AZ31 Featured

AZ31 is a novel ATM inhibitor.

2088113-98-6
DC10891 AZ-32 Featured

AZ32 is an orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) that radiosensitizes intracranial gliomas in mice.

2288709-96-4
DC9309 AZD-0156 Featured

AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities.

1821428-35-6
DC8468 AZD-6738 Featured

AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

1352226-88-0
DC10526 BAY-1895344 HCl(Elimusertib) Featured

BAY-1895344 is a potent and selective ATM inhibitor. BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride.

1876467-74-1
DC4112 CP466722 Featured

CP-466722 is an potent and reversible ATM inhibitor.

1080622-86-1
DC10080 GJ103 sodium salt Featured

GJ103 sodium salt is an active analog of the read-through compound GJ072.

1459687-96-7
DC1067 KU-55933 Featured

KU-55933 is a potent and specific ATM inhibitor with IC50 and Ki of 13 nM and 2.2 nM, respectively.

587871-26-9
DC7448 KU-60019 Featured

KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM.

925701-46-8
DC3132 VE-821 Featured

VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki and IC50 of 13 nM and 26 nM, respectively.

1232410-49-9
DC39113 VX-803 (M4344)

VX-803 (M4344) is an ATP-competitive, orally active, and selective inhibitor of ataxia telangiectasia and Rad3 related (ATR) kinase with Ki of < 150 pM. VX-803 (M4344) potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (P-Chk1) phosphorylation with IC50 of 8 nM. VX-803 (M4344) exhibits potential antineoplastic activity.

1613191-99-3
DC47131 ATR inhibitor 4

ATR inhibitor 4 (compound 121) is a potent ATR inhibitor. ATR inhibitor 4 has antitumor activity.

2417489-10-0
DC48118 ATR-IN-4

ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC50s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13).

2574545-45-0
DC48827 ATR-IN-7

ATR-IN-7 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-7 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021238999A1, compound 1).

2741917-74-6
DC48974 SKLB-197

SKLB-197 showed an IC50 value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

2713577-16-1
DC49019 ATR-IN-10

ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC50 value of 2.978 μM.

2713577-93-4
DC49031 ATR-IN-5

ATR-IN-5 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-5 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent CN112047938A, compound D24).

2601571-19-9
DC49061 ATR-IN-6

ATR-IN-6 is a potent inhibitor of ATR. ATR is a class of protein kinases involved in genome stability and DNA damage repair, and is a member of the PIKK family. ATR-IN-6 has the potential for the research of ATR kinase-mediated diseases such as proliferative diseases and cancer (extracted from patent WO2021233376A1, compound A22).

2746446-99-9
DC49543 ATR-IN-11

ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent drug discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease.

DC49544 ATR-IN-12

ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC50 value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent drug discovery targeting ATR kinase.

DC70062 BAY-1895344 hydrochloride

BAY-1895344 is a potent, selective, orally active ATR inhibitor with low-nanomolar potency.

DC70580 M3541

M3541 (M 3541) is a novel potent, selective and ATP-competitive ATM kinase inhibitor with IC50 of 0.25 nM (ATP, 10 uM).M3541 displays a good margin of selectivity (>60-fold) against the closely related PIKK family members with DNA-PK, PI3K isoforms, mTOR, and ATR.M3541 inhibits the phosphorylation of ATM as well as its cellular substrates CHK2, KAP1, and p53 in a concentration-dependent manner in A549 cells.M3541 inhibits double strand break repair and sensitizes cancer cells to radiation.M3541 suppresses ATM pathway activity and potentiates radiation efficacy in xenograft models of human cancer, synergizes with topoisomerase and PARP inhibitors.

1360628-91-6
Page 1 / Total 2 FirstPrevNextLastGoto